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Abstract
Background: HIV resistance affects virological response to therapy and efficacy of prophylaxis in mother-to-child-
transmission. The study aims to assess the prevalence of HIV primary resistance in pregnant women naïve to
antiretrovirals.
Methods: Cross sectional baseline analysis of a cohort of HIV + pregnant women (HPW) enrolled in the study
entitled Antiretroviral Management of Antenatal and Natal HIV Infection (AMANI, peace in Kiswahili language). The
AMANI study began in May 2010 in Dodoma, Tanzania. In this observational cohort, antiretroviral treatment was
provided to all women from the 28th week of gestation until the end of the breastfeeding period. Baseline CD4 cell
count, viral load and HIV drug-resistance genotype were collected.
Results: Drug-resistance analysis was performed on 97 naïve infected-mothers. The prevalence of all primary drug
resistance and primary non-nucleoside reverse-transcriptase inhibitors resistance was 11.9% and 7.5%, respectively.
K103S was found in two women with no M184V detection. HIV-1 subtype A was the most commonly identified,
with a high prevalence of subtype A1, followed by C, D, C/D recombinant, A/C recombinant and A/D recombinant.
HIV drug- resistance mutations were detected in A1 and C subtypes.
Conclusion: Our study reports an 11.9% prevalence rate of primary drug resistance in naïve HIV-infected pregnant
women from a remote area of Tanzania. Considering that the non-nucleoside reverse-transcriptase inhibitors are
part of the first-line antiretroviral regimen in Tanzania and all of Africa, resistance surveys should be prioritized in
settings where antiretroviral therapy programs are scaled up.
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Background
In 2010, 5 million people had access to HIV treatment in
Sub-Saharan Africa, about 49% of those in need. In
Eastern and Southern Africa, 56% of eligible patients had
access to therapy, versus 10% treated in 2009 [1]. The
scale-up of HIV treatment in low- and middle-income
countries has been crucial to substantially reduce AIDS-
related morbidity and mortality as well as mother-to-
child-transmission (MTCT). As access to antiretroviral
therapy expands, HIV drug resistance (HIVDR) inevitably
emerges because of HIV’s high mutation rate, viral recom-
bination, and the patient’s need for sustained, lifelong
treatment. The probability of drug resistance escalation
during treatment has been estimated at 27% every 6 years
[2]. The HIVDR insurgence may be related to a different
mechanism. It could be due to drug pressure in patients
receiving antiretroviral therapy (ART) because of subop-
timal adherence, pharmacodynamic factors, or use of
inadequate or suboptimal regimes. In recently infected in-
dividuals, HIVDR may be transmitted from one individual
to another. Finally, HIVDR can be transmitted or acquired
in individuals with chronic infections.
* Correspondence: francvairo@gmail.com
1“L. Spallanzani” National Institute for Infectious Diseases- INMI, Via Portuense
292, 00149 Rome, Italy
Full list of author information is available at the end of the article
© 2013 Vairo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Vairo et al. BMC Infectious Diseases 2013, 13:439
http://www.biomedcentral.com/1471-2334/13/439
The implications of transmitted drug resistance are a
cause of concern for the scaling up of HIV programs, as
HIV resistance also affects the efficacy of MTCT
prophylaxis.
Drug sensitivity testing (DST) is the standard of care
in industrialized countries, but is rarely available in
resource-limited settings due to high costs and stringent
requirements for storage and transport of plasma. With
the introduction of antiretroviral drugs in low-resource
countries (known for the largest assortment of non-B
subtypes), gaining a better understanding of the respon-
siveness to antiretroviral therapy and HIV-1 drug resist-
ance in non-B strains has become a priority. In such
settings, patients who do not respond to therapy are
often blindly switched from a non-nucleoside reverse
transcriptase inhibitor (NNRTI) to a protease inhibitor
(PI)-based regimen. However, since treatment failure is
detected late in most patients (at a stage when wide-
spread resistance is common), the risk of switching to
regimens with limited efficacy increases.
Among determinant factors driving the emergence of
HIVDR, virus- related factors play a crucial role in the
susceptibility to drug- resistance mutations. Viral sub-
types other than B share different ARV susceptibilities
compared to HIV-1 non-B subtypes, which are naturally
more or less susceptible to specific drugs. Different
results were obtained in several studies that have
compared the prevalence of drug-related mutations in
different HIV-1 non-B subtypes [3]: the recombinant
form CRF02_AG is reported to be more susceptible to
nelfinavir (NFV) and ritonavir (RTV) than C and F sub-
types; G subtype is more sensitive to tipranavir (TPV)
and lopinavir (LPV) than other subtypes [4], and C sub-
type has a greater risk of developing resistance to
tenofovir (TDF) [5]. In a Ugandan study [6], the K103N
mutation was relatively more frequent in C subtype-
infected women failing NNRTI-based therapy than in
both A and D subtypes. The G190A/S mutation was
considered a common polymorphism in Israeli C sub-
type patients, but not in Indian C subtype individuals
[7,8]. Despite the variability of non-B HIV-1 subtypes in
viral mutational patterns and in vitro susceptibility, the
benefit of treatment programs clearly outweigh the risks
of emerging HIV DR [3-8].
Future clinical studies designed to provide clinical
and virological data in non-B strains are of great
interest. Additional information on the prevalence of
drug-resistance mutations in naïve HIV populations
could be crucial for tailoring combination regimens.
Furthermore, it could help clinicians to decide whe-
ther DST prescription is necessary before initiating
therapy.
This study aims to assess the prevalence of HIV drug-
related resistance and the circulation of non-B subtype
in pregnant women naïve to antiretrovirals in Dodoma
region, central mainland Tanzania.
Methods
Study design
The data provided are part of a nested case-control
study of HIV resistance outcome among the HIV +
pregnant women (HPW) enrolled in the study entitled
Antiretroviral Management of Antenatal and Natal HIV
Infection (AMANI, peace in Kiswahili language). The
AMANI study is an interventional study which aims to
assess the feasibility of ART use for preventing MTCT
in a cohort of HIV-infected pregnant women. HAART is
provided to all women starting at the 28th week of gesta-
tion until the end of the breastfeeding period, within an
integrated MTCT prevention program. A systematic
screening during a formal interview on previous ART
use including single-dose NVP is performed. Baseline
CD4 cell count, viral load, and HIV drug- resistance
genotypes are collected at baseline, during pregnancy
and lactation.
The current study analyzed a subgroup of 97 pregnant
women naïve to any antiretroviral treatment. In order to
be certain that there was no previous exposure to any
ARV, women were included in the study only if the first
HIV positivity was discovered during the current preg-
nancy. The AMANI study was approved by the Italian
Ethical Board of the “L. Spallanzani” National Institute
for Infectious Diseases in November 2009 and by the
Tanzanian Medical Research Coordinating Committee of
the National Institute of Medical Research (NIMR), with
certificate no. NIMR/HQ/R.8a/Vol.IX/907 in December
2009. All recruited women provided written informed
consent.
HIV sequencing
HIV genotype analysis was performed on plasma sam-
ples by using a commercially available HIV genotyping
kit (ViroSeq HIV-1 Genotyping System version 2.0,
Abbott Molecular).
In brief, RNA was extracted using a commercially
available kit (QIAamp RNA Viral Mini kit, Qiagen),
retrotranscribed by murine leukaemia virus RT, and amp-
lified with ampliTaq Gold polymerase enzyme. Pol ampli-
fied products (containing the entire Protease (99-aa) and
the first 320 amino acids of the Reverse Transcriptase)
were full-length sequenced in sense and antisense orienta-
tions, using seven different overlapping sequence-specific
primers by an automated sequencer (ABI 3130, Applied
Biosystems, Foster City, CA, USA) [9,10]. Sequence data
were analyzed by a specific HIV genotyping system soft-
ware that automatically assembles the seven sequence
segments into a consensus sequence, which is then com-
pared to a B reference strain. Sequences having a mixture
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of wild-type and mutant residues at single positions were
considered to have a mutation at that position. When the
mixture was between two different mutations, both
mutations were considered and reported. To classify and
identify polymorphisms and mutations associated with
resistance to ARVs, the FASTA sequences of the PR and
RT were analyzed using the freely available SDRM-2009
algorithm available in the Calibrated Population Resist-
ance tool (CPR), version 6.0 beta (http://cpr.stanford.edu/
cpr.cgi). The SDRM algorithm (the SDRM worksheet
shows all of the mutations present on the ANRS, HIVdb,
IAS-USA, Los Alamos, and Rega algorithm lists) [11] was
applied to determine the prevalence of primary ARV-
resistance mutations, using a list of drug-resistance muta-
tions that provide an estimate of resistance transmission
according to the WHO guidelines (http://hivdb.stanford.
edu/cgi-bin/AgMutPrev.cgi).
Genotypic sub typing
Pol subtype was determined using phylogenetic analysis
on HIV-1 pol-sequences. Briefly, the sequences were
aligned with HIV-1 reference sequences of all subtypes
(http://www.hiv.lanl.gov). The alignment was edited using
the BioEdit program version 7.0.5.3. The phylogenetic
analysis of pol aligned sequences was performed by the
maximum-likelihood method of MEGA version 5.05. The
transversion model (GTR + I + G) of nucleotide substitu-
tion was chosen using the Kimura two-parameter model
as the best-fitting evolution model for tree reconstruction.
The reliability of the branching patterns was evalu-
ated by bootstrapping (1,000 replicates). Only boot-
strap values >70% were evaluated. Subtype classification
was also confirmed by REGA subtype tool (http://www.
bioafrica.net/rega-genotype/html/subtypinghiv.html) and
COMET subtype tool (http://comet.retrovirology.lu/). To
improve the accuracy of subtype recombinant forms
and unique forms, RDP3 software (http://web.cbio.uct.
ac.za/~darren/rdp.html) and Splits Tree software (http://
www.splitstree.org/) were used.
Statistical analysis
Descriptive statistics were used to analyze the epidemio-
logical data. Chi- square tests were used to assess differ-
ences between groups with reference to the occurrence
of drug-resistance mutations. A univariate analysis was
performed to examine possible demographic, clinical
and viro-immunological factors related to the occur-
rence of drug-resistance mutations. The Chi-square test
was used for the categorical variable. The T-test was
used for comparison of the means for the quantitative
variable; Wilcoxon signed rank was used for comparison
of medians. The significant level was set at 0.05. All the
analyses were performed using SPSS for Windows 12.0
(SPSS Inc, Chicago, Illinois 60606, USA).
Results
The enrollment phase of the AMANI study started on
May 2010 at the Makole Urban Health Centre (Makole
UHC) in the municipality of Dodoma (Figure 1). During
the nineteen months, 4,138 pregnant women attended
the Ante Natal Clinic (ANC), and 326 (7.8%) of these
were found to be affected by HIV infection. Among
them, 103 (31.6%) HPW were not eligible for the study
(i.e. attending the ANC with gestational age >28 weeks),
3 (1%) refused to participate (due to fear of drug side
effects), and 220 (67.5%) were included in the study.
Thirty-six of them (16.4%) are currently under eva-
luation for inclusion in the study. Twenty-seven (14.7%)
of the remaining 184 (83.6% of 220) did not return after
the enrollment visit and 12 (6,5%) dropped out. Of the
remaining 145 (78.8%) patients, 33 (22.8%) were already
on HAART at enrollment. Among the 112 (77.2%)
HPWs not on HAART at baseline, 85 (75.9%) started
ART for prevention of MTCT at the 28th week of gesta-
tion, and 27 (24.1%) were eligible for therapy and started
HAART (Figure 1).
Of the 112 patients originally not on HAART, 97
mothers with a first HIV positivity during the current
pregnancy and with no reported previous ART use were
tested for drug resistance before starting any antiretro-
viral drug (Table 1): 53 (54.6%) and 27 (27.8%) were
defined as WHO stage 1 and 2, respectively. Unpro-
tected heterosexual intercourse was the risk factor for
HIV infection reported by all HPWs in the study. At
baseline, the median CD4 count was 392 (IQR, 260-528)
cells/mm3 and Median log10 HIV RNA copies/mL was
4.80 (IQR, 4.03-9.28). The HIV genotypic drug-
resistance assay provided valuable results in 67 cases
(69.0%). The overall prevalence of primary drug resist-
ance was 11.9% (8/67; 95% CI 0.04-0.20); the prevalence
of primary drug class-specific resistance was 1.5% (1/67;
0.01-0.04) for nucleoside reverse-transcriptase inhibitors
(NRTIs) and 7.5% (5/67; 0.01-0.14) for NNRTIs. K103S
and M41L were found in two and one women, res-
pectively, while M184V was not detected. Interestingly,
L89M protease polymorphism (potentially associated
with resistance to fosamprenavir, and to a lesser extent
to darunavir and lopinavir) was commonly detected with
a 76.1% prevalence, equally distributed in all different
non-B clades.
K103N and M41L mutations were on five lists and the
K103S mutation was on four lists.
The HIV-1 A subtype was the most commonly identi-
fied (36/67, 53.7%) with a high prevalence of A1 subtype
(31/67, 47%), followed by C (14/67, 21%), and D (9/67,
13%). Furthermore, some circulating recombinant forms
(CRFs): CRF10_CD (8/67, 12%), CRF35_AD recombi-
nant (1/67, 1%) and some unique recombinant forms
(URFs) A1/C recombinant (4/67, 6%) were reported.
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The phylogenetic tree appears to show a cluster of
related infections in this geographical area, particularly
in A1 and C subtypes (Figure 2). Finally, two K103S
drug-related mutations and one K103N polymorphism
were all clustered in the A1 subtype. Pregnant women
with HIV viral strains harboring drug-resistance muta-
tions before any antiretroviral treatment did not signifi-
cantly differ from women with wild-type HIV in terms
of demographic, clinical, virological and immunological
parameters (Table 2).
Discussion
This cross sectional study shows an 11.9% overall pre-
valence of HIV primary drug resistance with a 7.5%
NNRTI-related resistance in naïve pregnant women.
The recent HIV drug resistance report, released by
WHO in November 2012 [12], reports the available data
on the estimated prevalence of HIVTDR between 2003
and 2010 in 72 surveyed areas. WHO recommends a
minimum-resource method to assess HIVTDR in
resource-limited countries where transmitted HIV drug
resistance is likely to be seen first (such as in urban
areas). Of the 72 surveys, 52 (72.2%) had a low preva-
lence of resistance to all drug classes and 20 (27.8%) had
a moderate prevalence classification of resistance to ≥1
antiretroviral drug class). The first reports from Tanzania
in 2005 showed a 4% and 9% NNRTI resistance in naïve
populations from the Kagera-Kilimanjaro regions and
Dar-es-Salaam urban area, respectively [13,14]. More
recently, in 2011, a 14.7% HIVDR prevalence in a naïve
population was reported in Mwanza [15]. Authors com-
bined drug-resistance prevalence data obtained from both
peripheral blood mononuclear cells (PBMC) and plasma,
whereas only 4 samples (9.5%) resulted positive at bulk
Figure 1 Total clinic attendance and patients recruited in the AMANI Study in Makole Health Centre after 19 months: enrollment algorithm.
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sequencing assay from plasma [15]. The NNRTI preva-
lence rates observed in these surveys are slightly higher
than those observed in previous reports in other eastern
and western African countries.
Reports showed the effect of a proper timing for intro-
duction of ART, as a proxy for the amount of circulating
drug-resistance HIV-1 strains at the population level,
and level of primary resistance [16]. The overall sample-
weighted drug resistance prevalence was 5.6% (139 of
2436; 95% CI 4.6–6.7), ranging from 1.1% (two of 176;
0.0–2.7) in Pretoria, South Africa, to 12.3% (22 of 179;
7.5–17.1) in Kampala, Uganda [16].
Regarding PI mutations, no major resistance muta-
tions were observed in our study. Nevertheless, the
76.1% prevalence of the L89M protease polymorphism
raises concern. Some amino acid polymorphisms occur
at sites that have been associated with drug resistance in
the B-subtype virus [9]. The L89M mutation increases
the catalytic efficiency and vitality of the HIV-1 protease
gene in the presence of other protease mutations in
non-B African viral subtypes [17] and can determine a
low accumulation of primary protease mutations in non-
B subtypes [18,19]. These findings suggest that in
addition to the primary drug-related mutations already
described in B clades, particular attention should be paid
to some natural polymorphisms in the therapeutic man-
agement of patients infected by HIV-1 non-B subtypes.
Our study aimed to determine the prevalence of trans-
mitted HIV drug-resistance mutations among untreated
patients and also provided novel data on the HIV-1 vari-
ants that circulate in Tanzania. We confirmed previous
results that reported a high genetic diversity in the num-
ber of co-circulating variants with the predominance of
A clade (53.7%), and a high prevalence of the A1 subtype
(47%). Different from a 2004 report that described a low
detection of drug resistance in A subtype compared to D
subtype [20], we reported that the primary NNRTI drug-
related mutations were all clustered in the A1 subtype.
This variant was described as one of the most prevalent
variants among young adults in Tanzania, Dar-es-Salaam
[14] and adults in the Kilimangiaro, Kagera and Mwanza
regions [13,15]. Thus, the implementation of a surveil-
lance study on the molecular epidemiology of different
HIV strains appears strictly complementary to the data
obtained from prevalence studies of drug-related muta-
tions using bulk sequencing.
Several limitations were encountered in our study.
Despite systematic screening of previous ART use, the
mean number of pregnancies is three and the risk of
unreported ART use in the AMANI cohort may be
significant. Nevertheless, most HIVDR mutations were
reported in parous women; the AMANI study was
conducted in a single area; a single population was
targeted, and the estimates of drug resistance have wide
CIs. However, despite all these considerations, the 11.9%
prevalence of drug resistance in a naïve population
where the first-line antiretroviral regimen is still based
on a NNRTI-based HAART raises concern. Further
work should be done to determine if resistance is a con-
sequence of short-term exposure during pregnancy or if
in fact these individuals had already accessed ARVs.
Together, this information could be used to guide the
development of ART policy guidelines in Tanzania.
Against this background, the increasing rates of anti-
retroviral resistance in adults and children from low-
income settings represent a potential threat and urgent
actions are needed. First, human and resource efforts
should be doubled to deploy proven effective preventive
methods. Second, early and sustained ART use for
preventing MTCT must be fully embraced [21] and the
recent 2012 WHO programmatic update on HIV PMTC
Table 1 Baseline clinical and viro-immunological
characteristics of 97 HIV-infected pregnant women naive




Age, years, mean ± SD; median, (IQR) 29,±5; 28 (25–32)
Gestational age at enrolment, week, mean ± SD 20 ± 5
Height at screening, cm, median (IQR) 155 (153–159)
Race/ethnicity, n. (%)
Black African 97 (100)
Education, n. (%)
Primary school 66 (68.0)
Secondary school 17 (17.5)
Other or unknown 14 (14.5)
Number of pregnancies, mean ± SD 3 ±1
Number of deliveries, mean ± SD 2 ±1
Number of children, mean +/-SD 1 ±1
HIV risk factor, n. (%)
Unprotected heterosexual relationship 97 (100)





Days since HIV diagnosis, median (IQR) 136 (94–164)
MedianCD4+ cells at enrolment /μL (IQR) 392 (260–528)
Median log10 HIV RNA copies/mL (IQR) 4.80 (4.03–9.28)
Eligible for HAART, n (%) 19 (19.6%)
Positive VDRL assay, n (%) 3 (3.1)
Note. IQR Interquartile Range, SD Standard Deviation.
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Figure 2 Phylogenetic tree of different non-B subtypes in 67 HIV-infected naive pregnant women with valuable results from the HIV
genotypic drug-resistance assay.
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transmission [22] should be strongly supported to provide
the option B-plus, the use of a life-long triple therapy for
the pregnant women.
Conclusion
Despite all the discussed considerations, the 11.9%
prevalence of drug resistance in a naïve population
where the first-line antiretroviral regimen is still based
on a NNRTI-based HAART raises concern. Further
work should be done to determine if resistance is a con-
sequence of short-term exposure during pregnancy or if
in fact these individuals had already accessed ARVs.
Together, this information could be used to guide the
development of ART policy guidelines in Tanzania.
Against this background, the increasing rates of anti-
retroviral resistance in adults and children from low-
income settings represent a potential threat and urgent
actions are needed. First, human and resource efforts
should be doubled to deploy proven effective preventive
methods. Second, early and sustained ART use for
preventing MTCT must be fully embraced [21] and the
recent 2012 WHO programmatic update on HIV PMTC
transmission [22] should be strongly supported to
provide the option B-plus, the use of a life-long triple
therapy for the pregnant women.
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